Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

15. Januar 2019 12:00 ET | Quelle: OSE Immunotherapeutics

OSE Immunotherapeutics Receives First Notice of Allowance of a Patent for Use of Tedopi® to Treat Brain Metastasis

Granted by the Japanese Patent OfficeFurther Strengthens Global Intellectual Property Portfolio for Tedopi® in Immuno-Oncology NANTES, France, Jan. 15, 2019 (GLOBE NEWSWIRE) -- OSE...
03. Januar 2019 12:00 ET | Quelle: OSE Immunotherapeutics

OSE Immunotherapeutics to present at Biotech Showcase™ 2019 Conference

During JP Morgan Healthcare ConferenceSan Francisco, January 7-9, 2019 NANTES, France, Jan. 03, 2019 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE), today announced...
20. Dezember 2018 12:00 ET | Quelle: OSE Immunotherapeutics

OSE Immunotherapeutics Announces First Healthy Volunteers Dosed in Phase 1 Clinical Trial of OSE-127

Entry into clinical phase of this anti-IL-7 receptor antagonist A breakthrough approach for the treatment of inflammatory autoimmune diseases NANTES, France, Dec. 20, 2018 (GLOBE NEWSWIRE) -- OSE...
17. Dezember 2018 12:00 ET | Quelle: OSE Immunotherapeutics

OSE Immunotherapeutics Appoints Julien Perrier Chief Commercial Officer

Julien Perrier brings extensive immunotherapy business operation experience To prepare the best commercial alliance for Phase 3 NSCLC candidate Tedopi®To strengthen commitment to clinical FR104...
10. Dezember 2018 12:00 ET | Quelle: OSE Immunotherapeutics

OSE Immunotherapeutics Invited to Present Mechanistic Data on Clinical Stage Anti-Interleukin-7 Receptor Antagonist OSE-127 at Two International Scientific Conferences

Data presented at the Annual World Congress of Digestive Disease in Rome, Nov. 30 - Dec. 2, and at the Antigen-Specific Immune Tolerance Europe Summit in London, Dec. 10 - 12 Presentations...
26. November 2018 12:00 ET | Quelle: OSE Immunotherapeutics

OSE Immunotherapeutics Receives Belgian Authorization for a Phase 1 Clinical Trial to Evaluate Anti-IL-7 Receptor Antagonist OSE-127

NANTES, France, Nov. 26, 2018 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo: OSE) today announced authorization by Federal Agency for Medicines and Health Products (FAMH)...
20. November 2018 02:00 ET | Quelle: OSE Immunotherapeutics

OSE Immunotherapeutics and Oncology Physician Network GERCOR Announce Initiation of Phase 2 Clinical Trial to Evaluate Tedopi® in Combination with Opdivo® (nivolumab) in Pancreatic Cancer

The trial, sponsored and conducted by oncology group GERCOR, will be supported by Bristol-Myers Squibb and OSE ImmunotherapeuticsPancreatic cancer is an indication with significant unmet need and...
02. November 2018 03:00 ET | Quelle: OSE Immunotherapeutics

OSE Immunotherapeutics Regains Worldwide Rights to its CD28 antagonist FR104 from Janssen Biotech

OSE to pursue clinical development of FR104 to treat autoimmune diseasesFR104’s good phase 1 clinical safety profile and first efficacy signal support phase 2 testing NANTES, France, Nov. 02,...
30. Oktober 2018 13:00 ET | Quelle: OSE Immunotherapeutics

OSE Immunotherapeutics Presents Selective SIRP-alpha antibodies: OSE-172, a next-generation myeloid checkpoint inhibitor at the World Immunotherapy Congress

Basel, Oct. 29-31, 2018 NANTES, France, Oct. 30, 2018 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo: OSE) presented at the World Immunotherapy Congress held on Oct....
29. Oktober 2018 02:00 ET | Quelle: OSE Immunotherapeutics

OSE Immunotherapeutics Announces Publication in Nature Communications on Anti-IL-7 Receptor Antagonist (OSE-127)

Full Antagonist Mechanism of Action Demonstrated In VivoLong-term Control of Specific Memory T Cell Mediated Autoimmunity and Chronic Inflammation NANTES, France, Oct. 29, 2018 ...

Vorherige Seite